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A B S T R A C T
Knowledge of the diurnal variation in circulating omega-3 polyunsaturated fatty acids (n-3 PUFAs) may be an
important consideration for the development of dosing protocols designed to optimise tissue delivery of these
fatty acids. The objective of the current study was to examine the variation in plasma concentrations of eico-
sapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) over a 24-h period in healthy adults
under eating and sleeping conditions generally approximate to a free-living environment. Twenty-one healthy
participants aged 25–44 years took part in a single laboratory visit encompassing an overnight stay. EPA and
DHA were measured in plasma samples collected every two hours from 22:00 until 22:00 the following day, with
all meals being provided at conventional times. Cosinor analysis was used to estimate the diurnal variation in
each fatty acid from pooled data across all participants. A significant diurnal variation in the pooled plasma
concentrations of both fatty acids was detected. However, evidence of distinct rhythmicity was strongest for
DHA. The timing of the peak concentration of DHA was 17:43 with a corresponding nadir at 05:43. In com-
parison, the observed acrophase for EPA was delayed by three hours, occurring at 20:41, with a nadir at 08:41.
This is the first time that the diurnal variation in these important bioactive fatty acids has been described in a
sample of healthy adults following a normal pattern of eating and sleeping. In the absence of any dietary intake
of EPA and DHA, circulating levels of these fatty acids fall during the overnight period and reach their lowest
point in the morning. Consumption of n-3 PUFAs at night time, which counteracts this pattern, may have
functional significance.
1. Introduction
Following several decades of investigation into the effects of the
bioactive omega-3 polyunsaturated fatty acids (n-3 PUFAs) eicosa-
pentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-
3) on cognition, firm conclusions regarding their specific effects are still
to be drawn. Evidence from cross-sectional studies is generally con-
sistent: across the lifespan, increased consumption of n-3 PUFAs is as-
sociated with better cognitive function [1–5]. On the other hand, cri-
tical and systematic reviews of clinical trials are more tentative, often
citing methodological variations underpinning the inconsistency in the
evidence [6–8]. Recommendations regarding dose, duration of inter-
vention, outcome measures and populations from which study samples
are drawn are now being proposed, which may lead to stronger
evidence in time [6,7,9,10].
Due consideration is also being given to the formulation of the n-3
PUFA intervention itself, so that maximal delivery of DHA and/or EPA
to tissues is ensured [11–13]. With regards optimal digestion and ab-
sorption, a further factor that may influence the efficacy of n-3 PUFAs is
the time at which the supplement is consumed. Evidence from rodent
studies suggests circadian variation in lipid metabolism that may be an
important consideration. For example, under normal light-dark condi-
tions where animals have ab libitum access to food, the peak time for
lipid digestion and absorption and for fatty acid oxidation occurs at the
very beginning of the active/awake phase [14], suggesting consump-
tion of fats is more desirable in the morning.
Specific investigation of the diurnal variation of blood levels of n-3
PUFAs in humans is limited to two studies, the results from which do
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not agree. Cornelissen et al. [15] estimated peak whole blood (finger-
prick) concentrations of total n-3 PUFAs (EPA, DHA, alpha linolenic
acid, docosapentaenoic acid) collected from one male and one female to
occur shortly after 08:00, with an estimated nadir occurring at 20:00.
On the other hand, the highest concentrations of plasma EPA and DHA
were reported by Dallmann et al. [16] at around noon in their sample of
ten males, after which they rapidly declined. Whilst both studies re-
cruited a small number of participants, key methodological differences
between these studies may have influenced the reported findings. For
example, both participants in the study by Cornelissen et al. had a
number of health issues, and the authors reported that one of the par-
ticipants followed an odd schedule on the day of data collection that the
authors suspected may have affected the results. On the other hand,
despite the fact that all of the participants recruited to the study re-
ported by Dallmann et al. were healthy, the blood samples were col-
lected under a strict regimen of hourly feeding around the clock and
participants were not able to sleep under a constant routine protocol.
The current study therefore aimed to investigate the diurnal rhythm of
plasma concentrations of EPA and DHA in humans under normal eating
and sleeping conditions. The results described below comprise a sec-
ondary outcome from a larger study that also evaluated the bioavail-
ability of acute doses of n-3 oils, which together informed the design of
a randomised controlled trial investigating the effects of n-3 oils on
cognitive function.
2. Materials and methods
2.1. Participants
All study procedures were reviewed and approved by Yorkshire and
The Humber - Bradford Leeds National Health Service Research Ethics
Committee (REC 16/YH/0224) and were conducted according to the
principles of the Declaration of Helsinki. All participants gave their
written informed consent before inclusion in the study. The trial is re-
gistered at ClinicalTrials.gov (NCT02661698).
A convenience sample of 21 adults aged 25–44 years, recruited from
within the staff and student population of Northumbria University,
completed the study (n = 10 males, 11 females; mean age 31.86 years,
mean BMI 25.30 kg/m2 and self-reporting an average intake of 0.5
portions of oily fish per week). Participants declared themselves to be in
good health. Participant demographics are displayed in Table 1. Ex-
clusion criteria were: consumption of more than one oily fish meal per
week; BMI < 18 or > 35 kg/m2; high blood pressure (defined as sys-
tolic > 159 mmHg or diastolic > 99 mmHg); smoking; food allergies or
insensitivities; pregnancy; breast feeding; currently taking any dietary
supplements; sleep disturbances and/or taking sleep aid medication;
chronic health conditions; gastrointestinal problems; active infections
and any health condition that would prevent the fulfilment of the study
requirements. The study was conducted from March to October 2016 at
the Brain, Performance and Nutrition Research Centre (BPNRC),
Northumbria University, UK.
2.2. Study design
Participants attended four identical study visits. During the first of
these visits, all participants received a placebo treatment (olive oil
capsules) in a single blind design. This approach fulfilled a dual pur-
pose; the first was to meet the objective of the current paper, namely to
investigate the diurnal variation in plasma EPA and DHA. The second
was to serve as a ‘practice’ visit for a randomised controlled trial as-
sessing the enrichment of plasma fatty acids following bedtime con-
sumption of n-3 oils—which comprised the remaining three visits—as it
was anticipated some participants might not feel comfortable with the
extended, overnight laboratory protocol. Only data collected at the first
visit are presented here. Sample size was calculated for the intervention
study; the effect size from a previous in-house bioavailability study
(unpublished data) showed that the effect size for 24-h Area Under the
Curve (AUC) increase in plasma DHA and EPA concentrations following
DHA-enriched oil was f= 0.49. Assuming similar, large effect size, an a
priori calculation suggested that in order to achieve 80% power and
95% statistical confidence, the sample size required was 24, inclusive of
a 20% drop out rate.
The placebo treatment comprised three soft gelatine capsules pro-
viding a total of 3 g refined olive oil. The blinding and labelling of the
treatment was carried out on site by a third party who had no further
involvement in the study.
2.3. Procedure
Participants arrived at the Brain, Performance and Nutrition
Research Centre (BPNRC) at Northumbria University at 19:30 following
a minimum two-hour fast. They were immediately fitted with a cannula
and a sample was drawn to check the participant was comfortable with
the procedure and to check for patency; this sample was discarded. At
20:00, participants were given an evening meal consisting of pasta,
tomato sauce, grated cheese and olive oil (624 Kcal, 26 g fat). They then
rested until 22:00 when the treatment (i.e. olive oil) was administered
with 200 mL of water. Participants were then settled into their room in
the Northumbria Centre for Sleep Research (adjacent to BPNRC) and
lights out was at 22:30. Lights on was at 06:00 the following morning
and a breakfast of cereal and toast was served at 07:00 (504 Kcal, 13 g
fat). Participants spent the remainder of the visit in a comfortable
waiting room in BPNRC where they read, watched TV, listened to music
etc. Lunch, comprising a cheese sandwich, an apple and a sweet biscuit
(479 Kcal, 17 g fat), was provided at 12:00, and an afternoon snack was
provided at 16:00 comprising a yoghurt, a banana and a packet of
savoury cracker snacks (402 Kcal, 15 g fat). The identical evening meal
to the previous day was given at 20:00 and participants went home by
public transport or by taxi at 22:15. Hot drinks (e.g. tea, coffee) were
offered along with the study meals and participants drank water ad
libitum throughout the visit.
In total, from each participant, thirteen blood samples were drawn
for analysis via cannula, with the first being drawn immediately prior to
treatment administration at 22:00. Samples were then collected every
two hours on the hour for the remainder of the study visit. The last
sample was drawn at 22:00, twenty-four hours post treatment. Samples
were always collected prior to the study meals. To keep the vein patent
throughout the entire study visit, after each draw the vein was flushed
with 0.5 mL saline solution (PosiFlush, BD, UK).
2.4. Fatty acid analysis
Blood was collected in EDTA vacutainers that were refrigerated at
4 °C for a maximum of four hours before being processed. Samples were
then centrifuged for 20 min at 3000 x g at 4 °C. Resulting plasma was
pipetted off and frozen at−80 °C prior to analysis, which took place at
the University of Southampton.
Lipid was extracted from plasma using 5 mL of chloroform/
Table 1
Participant demographics. N = 21 including 10 males and 11 females.
Mean SD Min Max
Age (years) 31.85 6.44 25.00 44.00
Systolic BP (mmHg) 120.57 12.56 92.50 139.50
Diastolic BP (mmHg) 80.10 9.12 65.00 98.00
BMI (kg/m2) 25.30 3.76 18.68 33.02
Oily fish (portions/week) 0.50 0.40 0.00 1.00
Ethnicity (N)
White 12
Asian 6
Black 1
Hispanic 1
Mixed 1
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methanol (2:1; v/v) containing 0.2 M butylated hydroxytoluene as
antioxidant. 1 M sodium chloride (1 mL) was added and the sample
vortexed and then centrifuged. The lower solvent phase was aspirated
and evaporated to dryness under nitrogen at 40 °C. The lipid extract was
redissolved in 0.5 mL toluene and fatty acids were released from es-
terified lipids and simultaneously derivatized to methyl esters by in-
cubation with 1 mL 2% H2SO4 in methanol for a minimum of 2 h at
50 °C to form fatty acid methyl esters. The samples were then neu-
tralized and fatty acid methyl esters transferred into hexane for analysis
by gas chromatography. Fatty acid methyl esters were separated on a
BPX-70 fused silica capillary column (30 m x 0.2 mm x 0.25 µm,
manufactured by SGE) in a HP6890 gas chromatograph fitted with a
flame ionisation detector. Gas chromatography run conditions were as
described elsewhere [17]. Dipentadecanoyl phosphatidylcholine added
into the initial plasma sample was used as an internal standard for
quantification purposes and a Supelco® 37 Component FAME Mix was
used as a calibration reference standard (Sigma-Aldrich). Plasma con-
centrations of EPA and DHA are expressed as µg/mL.
2.5. Statistical analysis
In order to investigate the diurnal variation in plasma EPA and
DHA, data collected over the 24-h period were evaluated using cosinor
analysis. In this procedure, a cosine curve is fitted to the data based on
the least squares method from which the MESOR (Midline Estimating
Statistic of Rhythm; a mean value), amplitude (the difference between
the MESOR and peak plasma concentrations) and acrophase (time of
the peak plasma fatty acid concentration) parameters are estimated
[18,19]. In order to establish the presence of a common rhythm be-
tween participants, data points (µg/mL) from each participant were
firstly expressed as a percentage of their respective mean value and
then pooled for the cosinor analysis [15]. Four data points were missing
due to technical issues during blood sampling. These missing data were
imputed by averaging the value of the samples drawn immediately
prior to and after the missing sample. Linear regression was used to
determine the goodness of fit of the estimated cosine curve where the
R2 value, referred to here as Percentage Rhythm (PR), relates to the
percentage of the variability accounted by the curve and the p value of
the F test is the likelihood of the data fitting a straight line as opposed to
a cosine curve [20].
A post-hoc exploratory analysis was carried out to assess the dif-
ference between males and females at each of the sampling time points.
This was conducted using the MIXED procedure in SPSS and included
the terms sample and sex. Subject was included as a random effect.
Significance was set at p < 0.05. Calculations of the cosine curve
parameters were made in Microsoft Excel 2016 and the regression
analyses were carried out in SPSS version 24 (IBM, USA).
In an exploratory analysis, the DHA and EPA data were analysed
separately for males and females. For both fatty acids, the rhythm was
phase advanced in females although this was more evident for DHA.
Specifically, the acrophase was estimated to occur at 16:16 in females
and 18:57 in males for DHA. For EPA, the estimated acrophase occurred
at 20:03 and 20:57 for females and males, respectively. Raw individual
data points, plotted as a function of time, are presented together with
the 24-h cosine curve for DHA and EPA in males and females separately
in Supplementary Material Fig. 2.
3. Results
Of the 25 participants who received treatment, four participants
withdrew from the study; in all cases this occurred during the study
visit due to feeling uncomfortable with the overnight blood sampling.
Mean (± SD) plasma fatty acid concentrations for EPA and DHA col-
lected at the first pre-treatment sample (22:00) were 14.27 ± 9.08 µg/
mL and 32.41 ± 14.07 µg/mL, respectively. When expressed as re-
lative percentages of total fatty acids (EPA, 0.87 ± 0.79; DHA,
1.94 ± 0.95), these values are largely in line with what has been
observed in other samples from the UK population [21].
Results from the cosinor analysis of the pooled data are presented in
Table 2. This table includes the cosinor analysis of all twenty-one fatty
acids that were quantified in the plasma samples, although only EPA
and DHA were of interest in the current study. A cosine curve, in-
dicating diurnal variation, was fitted to the data with statistical sig-
nificance for both DHA and EPA. In clock time, the acrophase for DHA
and EPA was estimated to occur at 17:43 and 20:41, respectively, with
the nadir of each occurring exactly 12 h previously (i.e. at 05:43 and
08:41, respectively). A similar pattern was observed for all analysed
fatty acids. Individual data points, plotted as a function of time, are
presented together with the 24-h cosine curve for DHA and EPA in
Fig 1. Plasma concentrations of DHA and EPA across the 24-h period for
each individual are presented in Supplementary Material Fig 1.
The results of the linear mixed model analysis showed no main ef-
fect of sex or interaction with time with regards the raw plasma con-
centrations (both p < 0.05). Data are displayed in Supplementary
Material Table 1.
4. Discussion
The current study aimed to investigate the diurnal variation of
plasma concentrations of the n-3 PUFAs EPA and DHA under eating and
sleeping conditions generally approximate to what might be considered
a ‘normal’ pattern for adults living in the UK. The cosinor analysis re-
vealed a significant diurnal rhythm for both DHA and EPA. Whilst there
was evidence of a similar general pattern for both these fatty acids and
indeed all the analysed fatty acids—where the lowest concentrations
were detected in the morning and the highest in the evening—the phase
was advanced by three hours for DHA, compared to EPA.
Apart from the obvious sleep-wake cycle, a number of physiological
functions including body temperature, blood pressure and metabolism
are known to oscillate daily in mammals [22]; therefore, our observa-
tion of the presence of diurnal variation in plasma EPA and DHA is
somewhat expected. Biological rhythms are controlled via clock genes
organized in a transcriptional feedback loop (e.g. Clock, Bmal1, Per and
Cry), with the ‘master clock’ located within the superchiasmatic nucleus
of the hypothalamus [23]. Clock-controlled genes have also been found
Table 2
Results from the cosinor analysis of pooled data with a period of 24 h.
Fatty acid N p PR A Φ Acrophase (hrs:min)
DHA 21 < 0.001 23.3 8.99 −94.18 17:43
EPA 21 < 0.001 13.5 7.76 −49.64 20:41
14:00 21 < 0.001 51.2 40.00 −85.93 18:16
16:00 21 < 0.001 36.7 12.70 −77.40 18:50
16:1n-7 21 < 0.001 8.2 7.47 −95.42 17:38
18:00 21 < 0.001 45 14.33 −69.40 19:22
18:1n-9 21 < 0.001 31.8 15.40 −50.84 20:36
18:1n-7 21 < 0.001 16.5 8.56 −65.94 19:36
18:2n-6 21 < 0.001 24 8.75 −57.81 20:08
18:3n-6 21 < 0.001 7.7 6.57 −109.21 16:43
18:3n-3 21 < 0.001 36.7 23.33 −55.47 20:18
20:00 21 < 0.001 36.2 22.80 −86.22 18:15
20:1n-9 21 < 0.001 19.2 14.69 −40.38 21:18
20:2n-6 21 < 0.001 8.2 6.67 −63.25 19:47
20:3n-6 21 < 0.001 24.4 10.80 −87.79 18:08
20:4n-6 21 < 0.001 24.9 8.92 −74.57 19:01
20:4n-3 21 0.077 1.9 5.29 −76.21 18:55
22:00 20 < 0.001 9.8 18.97 −64.66 19:41
22:5n-3 21 < 0.001 11.7 10.31 −104.40 17:02
24:00 21 0.001 5.5 6.20 −80.49 18:38
24:1n-9 21 0.002 4.5 7.01 −93.72 17:45
p, p-value derived from the regression test; PR, percentage rhythm or propor-
tion of variance in the data accounted for by the cosine wave (R2 x 100); A, 24-h
amplitude; Φ, acrophase or the time at which the peak amplitude occurs,
measured in degrees; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
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in most peripheral tissues, with a large number of physiological func-
tions controlled by endogenous circadian clocks that can oscillate in-
dependently from sleep and feeding cues [16]. To date, circadian
rhythms have been identified at all stages of lipid metabolism including
absorption, mitochondrial transport and partitioning [24]. Diurnal
variation is therefore evident in tissues such as plasma, and it would
appear that different lipid species display distinct rhythms in humans.
For example, in one study wherein circadian variation was measured
over a 28-h period, the acrophase of the majority of di- and triglycerides
occurred in the morning whereas peaks in phosphatidylcholine (PC)
species were observed in the evening [25]. Other trials have shown
diurnal variation in plasma free fatty acids, with peak concentrations
reported in the afternoon and evening [26,27].
Previous contradictory reports of the timing of the peak con-
centration of n-3 PUFAs specifically indicate that this occurred in the
morning [15] or at lunchtime [16], whereas we observed these to occur
in the evening. A key factor underpinning this observed difference
could be the more naturalistic pattern of eating and sleeping we aimed
to achieve with our protocol. Indeed, Singh et al. [28] reported peak
total plasma lipids at around 18:00 in 60 healthy young adults (21–40
years) who were synchronized to follow a diurnal pattern of eating and
sleep/activity similar to the current study. Given that the standard
meals provided to participants throughout the course of the study visit
were free from n-3 PUFAs, the observed diurnal rhythms for DHA and
EPA most likely reflect daily variations in the transfer of these fatty
acids between different lipid pools e.g. plasma phospholipids, trigly-
cerides, and cholesteryl esters, cellular phospholipids, and adipose and
other tissues. In plasma, higher levels of EPA and DHA are esterified to
phosphatidylcholine (PC) compared to other fractions after repeated
dosing [19]. Given that PC species have been shown to peak in the
evening [25,29], this suggests that the diurnal variation we observed
was probably for EPA and DHA esterified to phospholipids, and possibly
PC in particular. It is a limitation of the current study that the con-
centration of EPA and DHA was measured in total plasma lipids rather
than within specific lipid fractions, which would have enabled us to
address this issue directly.
In contrast to previous studies, we did not find any evidence of a
difference in absolute concentrations of DHA and EPA across the 24-h
Fig 1. Diurnal variation of pooled data (N = 21) in plasma concentrations of DHA (a) and EPA (b) expressed as a percentage of their respective mean 24-h value. A
significant rhythm is detected for both DHA and EPA. The equation of the cosine curve fitted by least squares to the data is presented on the graph. PR, percentage
rhythm or proportion of variance in the data accounted for by the cosine wave (R2 x 100).
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period between males and females. Previously, analysis of plasma me-
tabolites revealed that concentrations of unsaturated fatty acids were
higher in females and also more stable across BMI compared to males
[30]. In addition, total plasma lipids were reported to be higher in fe-
males than males regardless of age between 06:00 and 18:00 [28]. In
the current study, the sex differences in plasma concentrations of DHA
and EPA were analysed post hoc, and should therefore be interpreted
with caution, especially taking into consideration the small number of
participants included in this sub-group analysis. However, it is inter-
esting that we did observe a difference of almost three hours in the
acrophase of DHA, with females peaking earlier than males. This pat-
tern was also observed for EPA, but to a much lesser extent (~1-h). Sex
differences in the timing of melatonin secretion, body temperature,
sleep onset and the expression of clock genes in the brain have been
observed, with earlier timing consistently demonstrated in females
[31]. While hormonal differences such as the circadian rhythm of tes-
tosterone and the monthly fluctuations in estradiol and progesterone
have been cited as common reasons underpinning any observed dif-
ferences between males and females with regards lipid metabolism, it
has also been argued that the action of insulin, also known to vary by
sex, could be key [32]. Therefore, future studies designed specifically to
investigate sex differences in diurnal variation of lipid metabolism
should seek to control for monthly hormonal fluctuations, menopausal
status and insulin- and glucoregulation.
It has been demonstrated that lipid metabolism in humans is under
endogenous circadian clock control [16]. However, although we ob-
served a significant diurnal variation in both EPA and DHA at the group
level, our data also revealed a great degree of inter-individual varia-
bility as evidenced by the low (<30%) percentage rhythm detected for
both fatty acids. This, coupled with the variability in the previously
reported rhythmicity of circulating levels of n-3 PUFAs [15,16], would
suggest some degree of entrainment with rest/activity and feeding cues.
We aimed to mitigate any circadian misalignment due to altered sleep
patterns with the exclusion of night shift workers from the study, and
all data were collected from April to October during British Summer
Time. However, a limitation of the current study is a lack of information
regarding participants’ average sleep and eating habits, which could
have been used to determine how closely the enforced laboratory
schedule actually mimicked their normal day. A seven-day entrainment
protocol—wherein participants follow the laboratory schedule at home
during the week prior to the study visit— could have also been im-
plemented, which may have helped to reduce inter-individual varia-
bility to some degree. However, our study is not the first to report such
variability. Indeed, based on evidence showing poor agreement in both
the presence and phase of rhythmicity between participants across all
lipid species [25], it has been suggested that there may be distinct
circadian metabolic phenotypes, which will require further investiga-
tion [24]. It must also be noted that although the amplitude of the
phase for plasma concentrations of EPA was significant, the percentage
rhythm value observed for the variation of EPA was much lower than
DHA, and especially so when considering females separately. This
finding echoes what has been observed previously [15], and suggests
that plasma EPA does not follow as predictable a daily variation as
DHA. One reason for this may be differences in fate and function be-
tween the two fatty acids with EPA—as an eicosanoid precursor—being
released from adipocytes and potentially other tissues in response to
spontaneous endogenous changes such as inflammation, for example
[33,34].
The observed overnight decrease in DHA, and to a lesser extent EPA,
is interesting from a functional perspective. If regarded as a lipid
transport pool [19], the nocturnal decline in plasma concentrations of
these n-3 PUFAs suggests tissue uptake of these fatty acids during sleep.
The aim of the current study was to investigate the diurnal variation in
circulating plasma EPA and DHA, in order to inform optimal timing of
intake of these n-3 PUFAs in the context of maximising their tissue
delivery. The timing of delivery of DHA in particular may be important
for brain function, since the brain is especially enriched in this n-3
PUFA [35] that has key structural and functional roles. For example,
Umhau et al. [36] suggest that alterations in the specific composition of
newly formed neurons or synaptic membranes may underpin changes in
neuropsychiatric function following supplementation protocols of just a
few weeks that are unlikely to impact the overall concentration of brain
DHA. Adult hippocampal neurogenesis is known to occur during sleep
[37], and may play an important role in supporting learning and cog-
nitive flexibility [38,39] and memory consolidation [40]. Therefore, we
suggest that intake of n-3 PUFAs later in the evening—which would
ensure an overnight increase in plasma concentrations of EPA and DHA
at a time when background levels are at their daily lowest—presents as
a novel strategy to optimise the efficacy of n-3 PUFA supplementation
with regards cognitive function. Circadian studies in mice suggest that
lipid absorption is lowest at the end of the active/awake phase [41,42],
which would need to be taken into account if this dosing protocol was
adopted. Of course, testing this hypothesis by observing effects fol-
lowing morning and evening or indeed afternoon dosing protocols
would be required. What the data presented herein suggest more con-
cretely, is that the time at which DHA and EPA plasma samples (and
other fatty acids more broadly) are collected is an important con-
sideration. Therefore it is recommended that within the same study,
samples should be collected at the same time; any conclusions drawn
from comparisons to data presented by other studies should be mindful
of differences in sampling time points as well.
In conclusion, the current study revealed the presence of diurnal
variation in plasma concentrations of EPA and DHA in a sample of
healthy young adults with low habitual oily fish consumption. We ob-
served that peak concentrations occur towards the end of the day and
fall overnight, with the nadir of each fatty shown to occur in the
morning. We suggest that an evening dosing protocol may have im-
plications for efficacy studies with regards cognitive function, which we
aim to address in the future. Lastly, given their daily variation, caution
should be exercised when comparing absolute concentrations of plasma
fatty acid concentrations across studies.
CRediT authorship contribution statement
Philippa A. Jackson: Conceptualization, Methodology, Formal
analysis, Writing - original draft, Visualization, Project administration.
Cathrine Husberg: Conceptualization, Methodology, Writing - review
& editing, Project administration. Svein-Olaf Hustvedt:
Conceptualization, Methodology, Supervision, Writing - review &
editing. Philip C. Calder: Conceptualization, Methodology, Resources,
Writing - review & editing. Julie Khan: Investigation, Methodology,
Writing - review & editing. Hannah Avery: Investigation,
Methodology, Writing - review & editing. Joanne Forster:
Investigation, Methodology, Writing - review & editing. David O.
Kennedy: Conceptualization, Methodology, Writing - review & editing.
Declaration of Competing Interest
C.H and S.O.H are employees of BASF AS. P.C.C. is an advisor to and
has received funding from BASF AS.
Acknowledgements
The authors would like to thank Ellen Smith and Filomena Salvatore
for their assistance in collecting the data. We also thank Annette West
and Christiaan Gelauf for their contributions to the fatty acid analysis.
Funding sources
This study was funded by BASF (CTN00716202) AS.
P.A. Jackson, et al. Prostaglandins, Leukotrienes and Essential Fatty Acids 154 (2020) 102054
5
Supplementary materials
Supplementary material associated with this article can be found, in
the online version, at doi:10.1016/j.plefa.2020.102054.
References
[1] P. Montgomery, J.R. Burton, R.P. Sewell, T.F. Spreckelsen, A.J. Richardson, Low
blood long chain omega-3 fatty acids in UK children are associated with poor
cognitive performance and behavior: a cross-sectional analysis from the DOLAB
study, PLoS One 8 (2013).
[2] M. Adjepong, W. Yakah, W.S. Harris, R.A. Annan, M.B. Pontifex, J.I. Fenton, Whole
blood n-3 fatty acids are associated with executive function in 2-6-year-old
Northern Ghanaian children, J. Nutr. Biochem. 57 (2018) 287–293.
[3] M. Fotuhi, P. Mohassel, K. Yaffe, Fish consumption, long-chain omega-3 fatty acids
and risk of cognitive decline or Alzheimer disease: a complex association, Nat. Clin.
Pract. Neurol. 5 (2009) 140–152.
[4] V. Solfrizzi, V. Frisardi, C. Capurso, A. D’Introno, A.M. Colacicco, G. Vendemiale,
A. Capurso, F. Panza, Dietary fatty acids in dementia and predementia syndromes:
epidemiological evidence and possible underlying mechanisms, Ageing Res. Rev. 9
(2010) 184–199.
[5] M.F. Masana, A. Koyanagi, J.M. Haro, S. Tyrovolas, n-3 Fatty acids, Mediterranean
diet and cognitive function in normal aging: a systematic review, Exp. Gerontol. 91
(2017) 39–50.
[6] O.D. Rangel-Huerta, A. Gil, Effect of omega-3 fatty acids on cognition: an updated
systematic review of randomized clinical trials, Nutr. Rev. 76 (2018) 1–20.
[7] W. Stonehouse, Does consumption of LC Omega-3 PUFA enhance cognitive per-
formance in healthy school-aged children and throughout adulthood? Evidence
from clinical trials, Nutrients 6 (2014) 2730–2758.
[8] R.E. Cooper, C. Tye, J. Kuntsi, E. Vassos, P. Asherson, Omega-3 polyunsaturated
fatty acid supplementation and cognition: a systematic review and meta-analysis, J.
Psychopharmacol. 29 (2015) 753–763.
[9] S.J. Meldrum, M.A. Smith, S.L. Prescott, K. Hird, K. Simmer, Achieving definitive
results in long-chain polyunsaturated fatty acid supplementation trials of term in-
fants: factors for consideration, Nutr. Rev. 69 (2011) 205–214.
[10] K. Yurko-Mauro, D.D. Alexander, M.E. Van Elswyk, Docosahexaenoic acid and adult
memory: a systematic review and meta-analysis, PLoS One 10 (2015) 18.
[11] A.L. West, G.M. Kindberg, S.O. Hustvedt, P.C. Calder, A novel self-micro-emulsi-
fying delivery system enhances enrichment of eicosapentaenoic acid and doc-
osahexaenoic acid after single and repeated dosing in healthy adults in a rando-
mized trial, J. Nutr. 148 (2018) 1704–1715.
[12] Y. Qin, H. Nyheim, E.M. Haram, J.M. Moritz, S.O. Hustvedt, A novel self-micro-
emulsifying delivery system (SMEDS) formulation significantly improves the fasting
absorption of EPA and DHA from a single dose of an omega-3 ethyl ester con-
centrate, Lipids Health Dis. 16 (2017) 204.
[13] K.C. Maki, O.M. Palacios, M.A. Buggia, R. Trivedi, M.R. Dicklin, C.E. Maki, Effects
of a self-micro-emulsifying delivery system formulation versus a standard omega-3
acid ethyl ester product on the bioavailability of eicosapentaenoic acid and doc-
osahexaenoic acid: a study in healthy men and women in a fasted state, Clin. Ther.
(2018).
[14] M.S. Bray, M.E. Young, Regulation of fatty acid metabolism by cell autonomous
circadian clocks: time to fatten up on information? J. Biol. Chem. 286 (2011).
[15] G. Cornelissen, C. Galli, F. Halberg, F. De Meester, P. Rise, A. Wilczynska-Kwiatek,
R.B. Singh, F. Guillaume, Circadian time structure of fatty acids and vascular
monitoring, J. Appl. Biomed. 8 (2010) 93–109.
[16] R. Dallmann, A.U. Viola, L. Tarokh, C. Cajochen, S.A. Brown, The human circadian
metabolome, Proc. Natl. Acad. Sci. USA. 109 (2012) 2625–2629.
[17] H.L. Fisk, A.L. West, C.E. Childs, G.C. Burdge, P.C. Calder, The use of gas chro-
matography to analyze compositional changes of fatty acids in rat liver tissue
during pregnancy, J. Vis. Exp. (2014).
[18] D.S. Minors, J.M. Waterhouse, Mathematical and statistical analysis of circadian
rhythms, Psychoneuroendocrinology 13 (1988) 443–464.
[19] L.M. Browning, C.G. Walker, A.P. Mander, A.L. West, J. Madden, J.M. Gambell,
S. Young, L. Wang, S.A. Jebb, P.C. Calder, Incorporation of eicosapentaenoic and
docosahexaenoic acids into lipid pools when given as supplements providing doses
equivalent to typical intakes of oily fish, Am. J. Clin. Nutr. 96 (2012) 748–758.
[20] S. Montagnese, B. Middleton, A.R. Mani, D.J. Skene, M.Y. Morgan, Sleep and
circadian abnormalities in patients with cirrhosis: features of delayed sleep phase
syndrome? Metab. Brain Dis. 24 (2009) 427–439.
[21] K.D. Stark, M.E. Van Elswyk, M.R. Higgins, C.A. Weatherford, N. Salem Jr., Global
survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid
in the blood stream of healthy adults, Prog. Lipid Res. 63 (2016) 132–152.
[22] E.D. Buhr, J.S. Takahashi, Molecular components of the Mammalian circadian
clock, Handb. Exp. Pharmacol. (2013) 3–27.
[23] J.J. Gooley, E.C.P. Chua, Diurnal regulation of lipid metabolism and applications of
circadian lipidomics, J. Genet. Genom. 41 (2014) 231–250.
[24] E. Poggiogalle, H. Jamshed, C.M. Peterson, Circadian regulation of glucose, lipid,
and energy metabolism in humans, Metabolism 84 (2018) 11–27.
[25] E.C.-P. Chua, G. Shui, I.T.-G. Lee, P. Lau, L.-C. Tan, S.-C. Yeo, B.D. Lam, S. Bulchand,
S.A. Summers, K. Puvanendran, S.G. Rozen, M.R. Wenk, J.J. Gooley, Extensive di-
versity in circadian regulation of plasma lipids and evidence for different circadian
metabolic phenotypes in humans, Proc. Natl. Acad. Sci. USA 110 (2013)
14468–14473.
[26] J. Broussard, M.J. Brady, The impact of sleep disturbances on adipocyte function
and lipid metabolism, Best Pract. Res. Clin. Endoc. Metab. 24 (2010) 763–773.
[27] J. Yoshino, P. Almeda-Valdes, B.W. Patterson, A.L. Okunade, S. Imai,
B. Mittendorfer, S. Klein, Diurnal variation in insulin sensitivity of glucose meta-
bolism is associated with diurnal variations in whole-body and cellular fatty acid
metabolism in metabolically normal women, J. Clin. Endocrinol. Metab. 99 (2014)
E1666–E1670.
[28] R. Singh, S. Sharma, R.K. Singh, G. Cornelissen, Circadian time structure of circu-
lating plasma lipid components in healthy Indians of different age groups, Indian J.
Clin. Biochem. 31 (2016) 215–223.
[29] J.E. Ang, V. Revell, A. Mann, S. Mantele, D.T. Otway, J.D. Johnston, A.E. Thumser,
D.J. Skene, F. Raynaud, Identification of human plasma metabolites exhibiting
time-of-day variation using an untargeted liquid chromatography-mass spectro-
metry metabolomic approach, Chronobiol. Int. 29 (2012) 868–881.
[30] S. Kochhar, D.M. Jacobs, Z. Ramadan, F. Berruex, A. Fuerholz, L.B. Fay, Probing
gender-specific metabolism differences in humans by nuclear magnetic resonance-
based metabonomics, Anal. Biochem. 352 (2006) 274–281.
[31] N. Santhi, A.S. Lazar, P.J. McCabe, J.C. Lo, J.A. Groeger, D.-J. Dijk, Sex differences
in the circadian regulation of sleep and waking cognition in humans, Proc. Natl.
Acad. Sci. 113 (2016) E2730–E2739.
[32] X. Wang, F. Magkos, B. Mittendorfer, Sex differences in lipid and lipoprotein me-
tabolism: it’s not just about sex hormones, J. Clin. Endocrinol. Metab. 96 (2011)
885–893.
[33] N. Rittig, E. Bach, H.H. Thomsen, S.B. Pedersen, T.S. Nielsen, J.O. Jørgensen,
N. Jessen, N. Møller, Regulation of lipolysis and adipose tissue signaling during
acute endotoxin-induced inflammation: a human randomized crossover trial, PLoS
One 11 (2016) e0162167-e0162167.
[34] W.E. Connor, R. Lowensohn, L. Hatcher, Increased docosahexaenoic acid levels in
human newborn infants by administration of sardines and fish oil during preg-
nancy, Lipids (31 Suppl) (1996) S183-187.
[35] R.K. McNamara, S.E. Carlson, Role of omega-3 fatty acids in brain development and
function: potential implications for the pathogenesis and prevention of psycho-
pathology, Prostaglandins Leukot. Essent. Fatty Acids 75 (2006) 329–349.
[36] J.C. Umhau, W.Y. Zhou, R.E. Carson, S.I. Rapoport, A. Polozova, J. Demar,
N. Hussein, A.K. Bhattacharjee, K.Z. Ma, G. Esposito, S. Majchrzak, P. Herscovitch,
W.C. Eckelman, K.A. Kurdziel, N. Salem, Imaging incorporation of circulating
docosahexaenoic acid into the human brain using positron emission tomography, J.
Lipid Res. 50 (2009) 1259–1268.
[37] P.J. Lucassen, P. Meerlo, A.S. Naylor, A.M. van Dam, A.G. Dayer, E. Fuchs,
C.A. Oomen, B. Czeh, Regulation of adult neurogenesis by stress, sleep disruption,
exercise and inflammation: implications for depression and antidepressant action,
Eur. Neuropsychopharmacol. 20 (2010) 1–17.
[38] C. Anacker, R. Hen, Adult hippocampal neurogenesis and cognitive flexibility -
linking memory and mood, Nat. Rev. Neurosci. 18 (2017) 335–346.
[39] S.Y. Yau, A. Li, K.F. So, Involvement of adult hippocampal neurogenesis in learning
and forgetting, Neural Plast. (2015) 717958(2015).
[40] T. Kitamura, K. Inokuchi, Role of adult neurogenesis in hippocampal-cortical
memory consolidation, Mol. Brain 7 (2014) 13 -13.
[41] M.M. Hussain, X.Y. Pan, Clock regulation of dietary lipid absorption, Curr. Opin.
Clin. Nutr. Metab. Care 15 (2012) 336–341.
[42] X.Y. Pan, M.M. Hussain, Clock is important for food and circadian regulation of
macronutrient absorption in mice, J. Lipid Res. 50 (2009) 1800–1813.
P.A. Jackson, et al. Prostaglandins, Leukotrienes and Essential Fatty Acids 154 (2020) 102054
6
